Research programme: Alzheimer's disease therapeutics/diagnostics - Oxford GlycoSciences/Pfizer
Latest Information Update: 24 Sep 2007
At a glance
- Originator Oxford GlycoSciences; Pfizer
- Developer Oxford GlycoSciences
- Class Protein diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 05 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
- 29 Mar 2001 Preclinical development for Alzheimer's disease (diagnosis) in England (unspecified route)
- 29 Mar 2001 Preclinical development for Alzheimer's disease in United Kingdom (unspecified route)